Filing Flows › Vertex Pharmaceuticals (VRTX) › Guidance & outlook
Vertex Pharmaceuticals (VRTX) guidance and outlook
Vertex Pharmaceuticals (VRTX) raised its guidance on Nov 2, 2026: Revenue $13.2B for FY2026; Revenue +150 bps for FY2026. Vertex Pharmaceuticals' 10-Q filed Nov 3, 2026 makes 21 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $13.2B | raised |
| Revenue | FY2026 | +150 bps | reaffirmed |
| Revenue | FY2026 | $500M | new |
From the earnings release filed Nov 2, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 3, 2026
- We are also preparing for the anticipated launch of
- We expect that the number of people with CF taking our medicines will continue to grow through new approvals and
- We expect to begin launches in European markets
- • We expect to complete enrollment in both Phase 3 clinical trials evaluating suzetrigine in diabetic peripheral
- • We are on track to conduct the pre-planned interim analysis for potential U.S. accelerated approval once the interim
- Enrollment and dosing are well underway, and we expect to complete
- We expect to advance VX-017 into pivotal development in 2027.
- We aim to serially innovate in our disease areas of interest and follow our first-in-class therapies with potential best-
- We have acquired multiple biotechnology companies over the last several years and expect
- We expect to continue to identify and evaluate
- believe RP’s position is contrary to the plain terms of the CFF Agreement and intend to vigorously defend our position under
- We expect to continue to invest in our research programs with a focus on creating transformative
Vertex Pharmaceuticals' latest quarter
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
Did Vertex Pharmaceuticals raise or lower its guidance?
Vertex Pharmaceuticals (VRTX) raised its guidance on Nov 2, 2026: Revenue $13.2B for FY2026; Revenue +150 bps for FY2026.
What does Vertex Pharmaceuticals expect?
We are also preparing for the anticipated launch of We expect that the number of people with CF taking our medicines will continue to grow through new approvals and We expect to begin launches in European markets
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.